This past month, there has been a new Parkinson’s medication that is FDA approved. This new medication is called CREXONT. CREXONT combines the extended-release parts and immediate-release parts of carbidopa/levodopa. This new medication can help people with PD have more ON time each day while experiencing less dyskinesia and requiring less daily doses.
How is this different from other forms of carbidopa/levodopa?
Every dose of oral immediate-release carbidopa/levodopa is effective for only a short period of time. This can lead to increased OFF time. Due to the short period of effectiveness, as Parkinson’s progresses so will the amount of medication you need. One unfortunate consequence of high dose and long term use of levodopa is dyskinesia. Dyskinesias are uncontrolled jerking movements that can be localized to one body area or full body movements.
CREXONT is currently the longest-lasting medication of oral carbidopa/levodopa. It lasts longer than other medication because the parts that contribute to the extended-release are coated in a “mucoadhesive polymer.” This allows the medication to stay in the areas of our digestive system that leads to more effective absorption, therefore a more consistent amount of carbidopa/levodopa.
CREXONT Trial
There has been a trial that tested CREXONT against immediate-release carbidopa/levodopa in over 500 people with PD. The study concluded that those that received CREXONT had significantly more ON time with less dyskinesia. CREXONT was believed to deliver quality ON time of 1.5 hours more than the immediate-release carbidopa-levodopa group. Finally, people with CREXONT took on average 3 doses a day, compared to 5 doses in the immediate-release group. The most common adverse side effect was nausea and anxiety.
CREXONT is expected to be available in the US on 9/23/24. Talk with your doctor if you think CREXONT may be helpful for you.
Source:
Comentários